1. This figure is based on figures of over 800 deals signed in 2011, each of which was worth approximately $200 million. It is based on data from the EvaluatePharma Deals Database.
2. Research for this chapter is based on Centocor’s company papers and the personal papers of Hubert Schoemaker (hereafter HS-PP) kindly provided by his widow Anne Faulkner Schoemaker and on oral interviews with Centocor’s employees undertaken by the author in collaboration with the Chemical Heritage Foundation which houses the interview transcripts. The author conducted all interviews listed below except where specified. Interview transcripts are kept at the Chemical Heritage Foundation.
3. For Koprowski’s biography see Vaughan, R. (2000). Listen to the Music: The Life of Hilary Koprowski. Springer.
4. HS-PP: Centocor, Centocor Oncogene Research Partners LP, June 9, 1984.
5. For the early development of monoclonal antibodies see Marks, L. “A Healthtech Revolution: The story of César Milstein and the Making of Monoclonal Antibodies.” www.whatisbiotechnology.org.